insights_auto
为什么 CRSP 上涨了 5.85%?
深入探索chevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
US$53.39
arrow_upward
+5.85%(+2.95) 1 天
US$54.10
arrow_upward
+1.33% (+0.71)bedtime盘后交易
休市： 10月9日, GMT-4 16:00:00 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 CRSP 生成关键数据洞见…
开盘价
US$50.82
最高价
US$54.07
最低价
US$50.52
市值
51.62亿
平均成交量
161.97万
成交量
147.21万
52 周最高价
US$78.00
52 周最低价
US$44.12
每股收益
-US$4.76
Beta 版
1.45
流通股数
9669.30万
员工人数
393
开盘价
US$50.82
最高价
US$54.07
最低价
US$50.52
市值
51.62亿
平均成交量
161.97万
成交量
147.21万
52 周最高价
US$78.00
52 周最低价
US$44.12
每股收益
-US$4.76
Beta 版
1.45
流通股数
9669.30万
员工人数
393
新闻报道
来自网络来源和新闻合作伙伴
Timothy Sykes
·
8小时前
CRSP Climbs As Buy Rating Holds And Key Data Nears
Stock Traders Daily
·
18小时前
Understanding Momentum Shifts in (CRSP)
Simply Wall Street
·
1天前
Upcoming CTX310 Data Could Test The Case For CRISPR Therapeutics Stock
资料
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Crispr Therapeutics AG简介